2-(生物素基酰胺基)乙醇 | 95611-10-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 生物素及其衍生物
• 中文名称: 2-(生物素基酰胺基)乙醇
• 英文名称: 5-[(3aS,4S,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-N-(2-hydroxyethyl)pentanamide
• CAS: 95611-10-2
• 化学式: C₁₂H₂₁N₃O₃S
• 分子量: 287.383
• InChiKey: UYBGABATOCWMIE-QXEWZRGKSA-N

物化性质

• 沸点：
  667.6±50.0 °C(Predicted)
• 密度：
  1.225±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  19
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  116
• 氢给体数：
  4
• 氢受体数：
  4

安全信息

• 储存条件：
  存储条件：2-8°C，干燥，密闭

反应信息

• 作为反应物：
  描述：

  2-(生物素基酰胺基)乙醇 在 吡啶 、 氢氟酸 、 四丁基氟化铵 作用下， 以 四氢呋喃 为溶剂， 生成 5-[(3aS,4S,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-N-(2-(18F)fluoranylethyl)pentanamide
  参考文献：
  名称：

  Synthesis of 18F-labelled biotin analogues

  摘要：

  我们采用一步 18F 标记策略制备了维生素生物素的三种标记类似物，由于生物素与阿维丁的高亲和力，这些类似物可用作示踪剂。标记化合物的衰变校正产率高达 35%，比放射性为 320 GBq/µmol。在原位评估时，这些类似物显示出与阿维丁的良好亲和力：在 5 分钟内，60-75% 的放射性标记化合物与阿维丁结合。与原生生物素的阻断实验表明，这种结合具有位点特异性。

  DOI：

  10.1002/jlcr.1913
• 作为产物：
  描述：

  D-生物素 在 ethylene dichloride hydrochloride 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 48.0h， 生成 2-(生物素基酰胺基)乙醇
  参考文献：
  名称：

  Detection of Protein S-Sulfhydration by a Tag-Switch Technique

  摘要：

  AbstractProtein S‐sulfhydration (forming ‐S‐SH adducts from cysteine residues) is a newly defined oxidative posttranslational modification and plays an important role in H2S‐mediated signaling pathways. In this study we report the first selective, “tag‐switch” method which can directly label protein S‐sulfhydrated residues by forming stable thioether conjugates. Furthermore we demonstrate that H2S alone cannot lead to S‐sulfhydration and that the two possible physiological mechanisms include reaction with protein sulfenic acids (P‐SOH) or the involvement of metal centers which would facilitate the oxidation of H2S to HS..

  DOI：

  10.1002/anie.201305876

文献信息

• [EN] SONODYNAMIC THERAPY<br/>[FR] THÉRAPIE SONODYNAMIQUE
  申请人：UNIV ULSTER

  公开号：WO2018220376A1

  公开（公告）日：2018-12-06

  The invention relates to microbubble complexes for use in methods of sonodynamic therapy which comprise a microbubble attached to or otherwise associated with one or more linking groups, each linking group being bound to at least one sonosensitising agent and at least one chemotherapeutic agent. It further relates to the microbubble complexes themselves and to pharmaceutical compositions which contain them. The invention is particularly suitable for the treatment of deep-sited tumors, in particular pancreatic cancer.

  该发明涉及微泡复合物，用于声动力疗法方法，该方法包括与一个或多个连接基团连接的微泡，每个连接基团与至少一个声敏感剂和至少一个化疗药物结合。该发明还涉及微泡复合物本身以及含有它们的药物组合物。该发明特别适用于治疗深部肿瘤，特别是胰腺癌。
• Transporter-Targeted Lipid Prodrugs of Cyclic Cidofovir: A Potential Approach for the Treatment of Cytomegalovirus Retinitis
  作者：Mitan R. Gokulgandhi、Megha Barot、Mahuya Bagui、Dhananjay Pal、Ashim K. Mitra

  DOI：10.1002/jps.23140

  日期：2012.9

  Cidofovir (CDF) and its cyclic analogue (cCDF) have shown potential in vitro and in vivo antiviral activity against cytomegalovirus (CMV) retinitis. However, hydrophilic nature of CDF may affect cell permeation across lipophilic epithelium and thus limit its effectiveness in the treatment of CMV retinitis. In the present study, we have tested a novel hypothesis, which involves chemical derivatization

  西多福韦（CDF）及其环状类似物（cCDF）已显示出针对巨细胞病毒（CMV）视网膜炎的体外和体内抗病毒活性。然而，CDF的亲水性可能会影响细胞通过亲脂性上皮细胞的渗透，从而限制了其在CMV视网膜炎治疗中的有效性。在本研究中，我们测试了一个新的假设，其中涉及将cCDF化学衍生为亲脂性转运蛋白靶向前药[通过与脂筏的碳链长度不同和钠依赖性多种维生素转运蛋白（SMVT）的靶向部分（生物素）结合]。我们已经合成并表征了cCDF的三种衍生物，包括生物素B-C2-cCDF，B-C6-cCDF和B-C12-cCDF。物理化学性质，例如溶解度，分配系数（正辛醇/水和眼组织），生物还原动力学，并确定了与SMVT转运蛋白的相互作用。在这些新型结合物中，B-C12-cCDF与SMVT转运蛋白的相互作用更高，具有最低一半的最大抑制浓度值，更高的细胞蓄积性和较高的组织分配率。在增加脂链长度的趋势中，即B-C12-cCDF>
• A Biotinylated Glycosylphosphatidylinositol (GPI) as the Universal Platform To Access GPI-Anchored Protein Analogues
  作者：Xin Yan、Jiatong Guo、Sayan Kundu、Zhongwu Guo

  DOI：10.1021/acs.joc.3c02560

  日期：2024.1.19

  A glycosylphosphatidylinositol (GPI) derivative with biotin linked to its mannose III 6-O-position was prepared by a convergent strategy. This biotinylated GPI was demonstrated to bind avidinated proteins readily through biotin–avidin interaction and, therefore, can serve as a universal platform to access various biologically significant GPI-anchored protein analogues.

  通过收敛策略制备了甘露糖 III 6-O-位上连接有生物素的糖基磷脂酰肌醇 (GPI) 衍生物。这种生物素化的 GPI 被证明可以通过生物素-亲和素相互作用轻松结合亲和蛋白，因此可以作为获取各种具有生物学意义的 GPI 锚定蛋白类似物的通用平台。
• Non-nucleotide reagents for substituting termini of oligonucleotides
  申请人：M.L. TECHNOLOGY VENTURES, L.P.

  公开号：EP0310312A2

  公开（公告）日：1989-04-05

  A reagent which can couple with the 5' hydroxy position of a nucleotide, typically the terminal nucleotide in a nucleotide multimer, under the same conditions used in known standard solid-phase nucleotide multimer synthesis. When so coupled, the reagent produces a substituted nucleotide multimer with a protected linking moiety which is deprotected under the same alkaline conditions typically used to deprotect nucleotide exocyclic amines of a completed synthetic nucleotide multimer. A single one of the class of reagents can be so coupled to any nucleotide, and since the reagents have a non-nucleotide skeleton, the resulting substituted nucleotide multimer does not have an additional nucleotide which could potentially interfere with hybridization with a target nucleotide sequence.

  一种试剂，可在已知的标准固相核苷酸多聚物合成所用的相同条件下，与核苷酸（通常是核苷酸多聚物中的末端核苷酸）的 5'羟基位置偶联。当这种试剂与核苷酸多聚物偶联时，就会产生一种具有受保护连接分子的取代核苷酸多聚物，这种核苷酸多聚物在通常用于对已完成合成的核苷酸多聚物的核苷酸外环胺进行脱保护的相同碱性条件下进行脱保护。该类试剂中的一个试剂可与任何核苷酸连接，由于试剂具有非核苷酸骨架，因此产生的取代核苷酸多聚体没有可能干扰与目标核苷酸序列杂交的额外核苷酸。
• Biotin amides, a process for their preparation and therapeutical compositions containing them as the active principles for the treatment of diabetes and relative complicating diseases
  申请人：LIFEGROUP S.p.A.

  公开号：EP0590563A1

  公开（公告）日：1994-04-06

  Biotin amides, a process for their preparation and therapeutical compositions containing them as the active principles for the treatment of insulin-independent and insulin-dependent diabetes and relative complicating diseases, such as peripheral neuropathies, chronic and invalidating pathologies.

  生物素酰胺、生物素酰胺的制备方法以及含有生物素酰胺作为活性成分的治疗组合物，用于治疗胰岛素依赖型和胰岛素依赖型糖尿病及相关并发症，如周围神经病、慢性病和致残性疾病。